Solid Tumor Clinical Trials

104 studies are recruiting for solid tumor in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 4

1. NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

   The goal of this clinical trial is to learn about the safety of NEROFE and doxorubicin and how well it works in patients with advanced/unresectable or metastatic solid KRAS-mutated and ST-positive solid tumors. The main question it aims to answer is to find the recommended dose and scheduled for th…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Georgetown Lombardi Comprehensive Cancer Center, Washington D.C., District of Columbia

   Run by

   Georgetown University

   See if you can join NCT05661201 on ClinicalTrials.gov

2. Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

   This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of tolododekin alfa (ANK-101) in participants with advanced solid tumors who have progressed during or after receiving standard of care (SOC) therapy or who will …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   National Cancer Institute, Bethesda, Maryland

   Locations

   5 in total

   Run by

   Ankyra Therapeutics, Inc

   See if you can join NCT06171750 on ClinicalTrials.gov

3. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

   This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Stern Center for Cancer Clinical Trials and Research, Orange, California

   Locations

   21 in total

   Run by

   I-Mab Biopharma US Limited

   See if you can join NCT04900818 on ClinicalTrials.gov

4. SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas

   The goal of this clinical trial is to learn what dose of the drug SB-4826 can be given safely in patients with solid tumors and non-Hodgkin lymphomas. This drug will be used alone in patients with solid tumors, and will be used alone or in combination with rituximab in patients with non-Hodgkin lym…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, San Diego, La Jolla, California

   Run by

   University of California, San Diego

   See if you can join NCT07222631 on ClinicalTrials.gov

5. Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

   The primary objective of this study is to improve the 2-year progression-free survival in children with high-risk solid tumors who are administered a maintenance regimen with continuous sirolimus administered on a backbone of metronomic chemotherapy following the completion of "standard" therapy, a…

   Stage

   Phase 2

   Ages

   1 to 30

   Site

   Aflac Cancer & Blood Disorders Centers, Atlanta, Georgia

   Locations

   5 in total

   Run by

   Emory University

   See if you can join NCT04469530 on ClinicalTrials.gov

6. Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

   This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks patients to volunteer to take part in a research study investigating the safety and efficacy of using special immune cell…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Baylor St. Luke's Medical Center, Houston, Texas

   Run by

   Baylor College of Medicine

   See if you can join NCT03740256 on ClinicalTrials.gov

7. FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors

   A Phase I, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AT03-65 in Adults with Advanced Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Oregon Health & Science University (OHSU), Portland, Oregon

   Run by

   Axcynsis Therapeutics Pte Ltd

   See if you can join NCT06809114 on ClinicalTrials.gov

8. A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

   This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute at HealthONE, Denver, Colorado

   Locations

   15 in total

   Run by

   OnCusp Therapeutics, Inc.

   See if you can join NCT06234423 on ClinicalTrials.gov

9. Study of PAT in Patients With Solid Tumor Cancers

   This is a single center Phase I study with extension of peptide alarm therapy (PAT) administered by intratumoral (IT) injection during the 1st course of a standard of care intravenous PD-1/PD-L1 inhibitor for the treatment of locally advanced or metastatic solid tumor cancers that has failed to be …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

   Run by

   Masonic Cancer Center, University of Minnesota

   See if you can join NCT05338658 on ClinicalTrials.gov

10. A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy

    A pilot study using remote monitoring technology developed by Locus Health in cancer patients undergoing chemotherapy treatment.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Inova Schar Cancer Institute, Fairfax, Virginia

    Run by

    Inova Health Care Services

    See if you can join NCT06106360 on ClinicalTrials.gov

11. Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection

    Overall, this project has three main goals: first, to ascertain the feasibility of the approach and identify whether liquid biopsies can detect actionable mutations that can be utilized to generate precision oncology treatment recommendations. Second, the investigators will investigate whether enac…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Johns Hopkins University, Baltimore, Maryland

    Run by

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT05585684 on ClinicalTrials.gov

12. A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

    The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or solid gynecological cancer.

    Stage

    Phase 2

    Ages

    18 to 99

    Site

    AdventHealth, Orlando, Florida

    Locations

    4 in total

    Run by

    University of Oklahoma

    See if you can join NCT05512208 on ClinicalTrials.gov

13. Umbilical Cord Blood Transplantation From Unrelated Donors

    This study is being done to determine how long it takes for the engraftment (recovery of blood cell counts) of umbilical cord stem cells and also how often engraftment of umbilical cord stem cells transplanted from an unrelated donor fails. Another purpose will be to document the rate of disease-fr…

    Stage

    Not phased

    Ages

    0 to 75

    Site

    Wilmot Cancer Institute, Rochester, New York

    Run by

    University of Rochester

    See if you can join NCT03016806 on ClinicalTrials.gov

14. A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

    This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    9 in total

    Run by

    ImmVira Pharma Co. Ltd

    See if you can join NCT04370587 on ClinicalTrials.gov

15. Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

    The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to targ…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Institut Jules Bordet, Brussels,

    Locations

    27 in total

    Run by

    Oxford BioTherapeutics Ltd

    See if you can join NCT04064359 on ClinicalTrials.gov

16. A Beta-only IL-2 ImmunoTherapY Study

    This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sharp Memorial Hospital, San Diego, California

    Locations

    27 in total

    Run by

    Medicenna Therapeutics, Inc.

    See if you can join NCT05086692 on ClinicalTrials.gov

17. FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

    The goal of this clinical trial is to investigate the safety, the activity of VERT-002 (PFL-002), and the optimal safe dose to be used, in participants with solid tumors including non-small cell lung cancer.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Georgetown Lombardi Comprehensive Cancer Center, Washington D.C., District of Columbia

    Locations

    19 in total

    Run by

    Pierre Fabre Medicament

    See if you can join NCT06669117 on ClinicalTrials.gov

18. First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

    The purpose of this study is to determine the safety, blood concentrations and treatment effect of CRB-601 in combination with immunotherapy in patients who have advanced solid tumors (cancer) and have exhausted other therapeutic options.CRB-601 targets a protein called avb8 integrin which is expre…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    SCRI- Lake Nona DDU, Orlando, Florida

    Locations

    26 in total

    Run by

    Corbus Pharmaceuticals Inc.

    See if you can join NCT06603844 on ClinicalTrials.gov

19. RAPA-201 Therapy of Solid Tumors

    The therapy of solid tumors has been revolutionized by immune therapy, in particular, approaches that activate immune T cells in a polyclonal manner through blockade of checkpoint pathways such as PD-1 by administration of monoclonal antibodies. In this study, the investigators will evaluate the ad…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Hackensack University Medical Center, Hackensack, New Jersey

    Run by

    Rapa Therapeutics LLC

    See if you can join NCT05144698 on ClinicalTrials.gov

20. Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

    This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Beijing Cancer Hospital, Beijing, Beijing Municipality

    Locations

    8 in total

    Run by

    Impact Therapeutics, Inc.

    See if you can join NCT05269316 on ClinicalTrials.gov

21. Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

    This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of TU2218 in combination with Pembrolizumab in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    CHA University Bundang Medical Center, Seongnam,

    Locations

    11 in total

    Run by

    TiumBio Co., Ltd.

    See if you can join NCT05784688 on ClinicalTrials.gov

22. BP1001-A in Patients With Advanced or Recurrent Solid Tumors

    This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or maximum administered dose (MAD) of BP1001-A as a single agent. After the MTD or MAD of BP1001-A is es…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Holy Cross Hospital, Silver Spring, Maryland

    Locations

    4 in total

    Run by

    Bio-Path Holdings, Inc.

    See if you can join NCT04196257 on ClinicalTrials.gov

23. Trial of DFP-14927 in Advanced Solid Tumors

    This is a Phase I, open-label, single-arm, dose escalation study of DFP-14927 intravenous infusion administered to patients with refractory or relapsed solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UCLA Department of Medicine- Hematology/Oncology, Los Angeles, California

    Locations

    2 in total

    Run by

    Delta-Fly Pharma, Inc.

    See if you can join NCT03943004 on ClinicalTrials.gov

24. Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

    This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab [Gazyva®] pre-treatment, by IV infusion, and in combination with pembrolizumab. A Phase 2 monotherapy arm is also planned;…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    HonorHealth Research Institute, Scottsdale, Arizona

    Locations

    6 in total

    Run by

    Simcha IL-18, Inc.

    See if you can join NCT04787042 on ClinicalTrials.gov

25. A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors

    The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of PTX-912 in patients with locally advanced or metastatic solid tumors. To evaluate the PK and immunogenicity profile of PTX-912. To evaluate the preliminary anti-tumor activity of PTX-912. Participants …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope National Medical Center, Duarte, California

    Locations

    3 in total

    Run by

    Proviva Therapeutics, Inc.

    See if you can join NCT06190886 on ClinicalTrials.gov